Sarcopenia clinical trials at UCSF
1 research study open to eligible people
Showing trials for
A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia
open to eligible males ages 18 years and up
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of LPCN 1148 in men with cirrhosis of the liver and sarcopenia.
San Francisco, California and other locations
Our lead scientists for Sarcopenia research studies include Jennifer Lai, MD, MBA.
Last updated: